

ONE HUNDRED EIGHTH LEGISLATURE

SECOND SESSION

LEGISLATIVE RESOLUTION 379

Introduced by Bostar, 29.

PURPOSE: The purpose of this resolution is to propose an interim study to examine the role of health insurance for biomarker testing and the use of biomarker testing in public and private payor markets. The study should also examine the barriers faced by Nebraska patients in accessing biomarker testing which can inform and personalize treatments for diseases and conditions such as cancer.

Health data shows that currently sixty percent of medical treatments in preclinical development rely on biomarker data. Biomarker testing includes, but is not limited to, single-analyte tests, multiplex tests, protein expression, and whole exome, whole genome, and whole transcriptome sequencing.

This study shall include, but need not be limited to, an examination of the following:

(1) The awareness of patients, providers, and insurers about precision medicine and biomarker testing in Nebraska;

(2) When available, the effectiveness of biomarker testing and related treatment and how biomarker testing is being used for an increasing range of conditions and diseases;

(3) Barriers to appropriate patient access and utilization of biomarker testing; and

(4) Current insurance coverage in both the public and private sectors.

NOW, THEREFORE, BE IT RESOLVED BY THE MEMBERS OF THE ONE HUNDRED EIGHTH LEGISLATURE OF NEBRASKA, SECOND SESSION:

1. That the Banking, Commerce and Insurance Committee of the Legislature shall be designated to conduct an interim study to carry out the purposes of this resolution.

2. That the committee shall upon the conclusion of its study make a report of its findings, together with its recommendations, to the Legislative Council or Legislature.